Profit
As we have seen from USG's comments and the Alterrus Quarterly's, ASIUF is not making a profit. We know this. However, they have been operating for a year now, and have yet to reach their full consumer and production potential. From the spring to summer, sales doubled. Since then they have tripled their customer base, increased product lines (with more products), and continue to improve their production process. To use their $210K last quarterly sales as the sale going forward to show they arent profitable is irresponsible. It is going to take them time to increase sales. Yes there are other general admin costs (Ng and Fane's salary included). But as I mentioned before, if they can show more revenue than COGS, then will be able to achieve more capital and more funding for more installations.
Ask USG this, if he/she doesnt believe Alterrus will be profitable any time soon (and what is that 10 years?), then why buy their stock. Also, they dont necessarily have to be profitable for the stock to jump. If they can show that they can generate revenue greater than COGS, they could attract a lot more outside investors attentions.
AGAIN, LET ME CAPS LOCK THIS. ALTERRUS SALES?REVENUE HAS NOT PEAKED YET. SO HOW CAN YOU SAY THAT THEY CAN NOT BE PROFITABLE IF YOU DO NOT KNOW THEIR PEAK REVENUE POTENTIAL. If they doubled revenue for the next 3 quarters, they would be making $1.6 Million a quarter (Now I am not saying that is going to happen, just that we have already seen sales double in one quarter, and it all depends on how fast sales grow, and how much).
One thing that hasnt grown quarter over quarter is cost of sales; $323K last quarter, and ~$316K the quarter before that. So it looks like that number is a good cost to use. If sales doubles another quarter, it would exceed cost of sales. AGAIN, I AM NOT SAYING ALTERRUS IS GOING TO BE PROFITABLE BY THE NEXT QUATERLY! Just saying they are moving closer and closer to it. I expect sales to have grown even more on their next quarterly statement.
News 
Market Data 
Discover 
